USPSTF Recommendations for the Management of Dyslipidemia for Cardiovascular Risk Reduction

Am Fam Physician. 2022 May 1;105(5):Online.
No abstract available

Publication types

  • Letter

MeSH terms

  • Cardiovascular Diseases* / prevention & control
  • Cardiovascular System*
  • Dyslipidemias* / drug therapy
  • Heart Disease Risk Factors
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Risk Factors

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors